Infectious Disease Center of Excellence

Supporting infectious disease patients

Orsini’s Infectious Disease Center of Excellence launched in 2023 with our first program for recurrent C. difficile infection. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Infectious Disease Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Patient-Centered Care

Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Infectious Disease Conditions Supported

Explore the infectious diseases Orsini supports below.

About Recurrent C. difficile Infection (rCDI)

Recurrent C. difficile infection is a gastrointestinal condition caused by the bacteria Clostridium difficile. It stems from an imbalance, known as dysbiosis, in the gastrointestinal microbiome. Associated with heightened morbidity and mortality, rCDI has been classified as an Urgent Health Threat by the Centers for Disease Control and Prevention (CDC).

rCDI Therapies Supported

Vowst™ (fecal microbiota spores live-brpk)

Full Name	Vowst™ (fecal microbiota spores live-brpk)
Drug	Vowst
Manufacturer	Aimmune Therapeutics
Route of Administration	Oral
Site of Care	Home
Approved Indication	Prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI)
Disease	Recurrent C. difficile Infection (rCDI)
Therapeutic Area	Infectious Disease; Gastroenterology
Enrollment Form Link	Vowst Enrollment Form
Phone Number	800-485-4885
Fax Number	877-640-5179
Product Website	vowsthcp.com